<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3250">
  <stage>Registered</stage>
  <submitdate>28/07/2011</submitdate>
  <approvaldate>28/07/2011</approvaldate>
  <nctid>NCT01406119</nctid>
  <trial_identification>
    <studytitle>An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors</studytitle>
    <scientifictitle>An Extension Study of ABT-806 for Subjects With Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>M12-326</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-806

Experimental: ABT-806 Arm - 


Treatment: drugs: ABT-806
ABT-806 will be administered by intravenous infusion.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety (Number of subjects with adverse events) - Evaluation of vitals signs, clinical lab testing and adverse event monitoring (every other week), physical exam (every 4 weeks) and ECG (at final visit)</outcome>
      <timepoint>At each treatment visit (every other week throughout the study or up to 51 weeks)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetic profile (assay for ABT-806) - Assay for ABT-806</outcome>
      <timepoint>Every 8 weeks starting at Week 9 throughout the study or up to 51 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject has completed a prior study utilizing ABT-806 or 111ln ABT-806 (ABT 806i) and
             the Investigator believes that continued treatment with ABT-806 is in the best
             interest of the subject.

          -  Women of childbearing potential and men must agree to use adequate contraception (one
             of the following listed below) prior to study entry, for the duration of study
             participation and for a period of 3 months. Female subjects considered not of
             childbearing potential must be documented as being surgically sterile or
             post-menopausal for at least 1 year.

          -  Subject is capable of understanding and complying with parameters as outlined in the
             protocol and the subject or the subject's legal acceptable representative is able to
             sign informed consent, approved by an Institutional Review Board (IRB) prior to the
             initiation of any or study-specific procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject discontinued ABT-806 or111ln ABT-806 (ABT-806i) administration before
             completing the prior study (due to disease progression, toxicity, withdrawn consent,
             other).

          -  Subject has any medical condition which in the opinion of the investigator places the
             subject at an unacceptably high risk for toxicities.

          -  Subject is a lactating or pregnant female.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 60619 - Heidelberg</hospital>
    <hospital>Site Reference ID/Investigator# 63845 - Herston</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an extension study of ABT-806 for subjects with advanced solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01406119</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christopher Ocampo, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>